Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F B Müller

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Schweizerische Medizinische Wochenschrift|November 15, 1986
[Secretion of atrial natriuretic peptide: relation to atrial pressure and systemic blood pressure]F B Müller, P Erne, A E Raine, et al.
Hypertension (Dallas, Tex. : 1979)|January 1, 1986
Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamilR J Cody, S H Kubo, A B Covit, et al.
Journal of Cardiovascular Pharmacology|January 1, 1985
Adrenoceptors, calcium, and vasoconstriction in normal and hypertensive humansF R Bühler, P Bolli, P Erne, et al.
The American Journal of Cardiology|December 6, 1985
Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonistsW Kiowski, F R Bühler, M O Fadayomi, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1987
Greater vasodilator responsiveness to atrial natriuretic peptide in low-renin essential hypertensivesP Bolli, F B Müller, L Linder, et al.
Pharmacological Research Communications|September 1, 1988
Pathophysiological role of atrial natriuretic peptide in manF R Bühler, F B Müller, A E Raine, et al.
Journal of Cardiovascular Pharmacology|January 1, 1989
The vasodilating effect of atrial natriuretic peptide in normotensive and hypertensive humansP Bolli, F B Müller, L Linder, et al.
British Journal of Clinical Pharmacology|January 1, 1985
Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once dailyF B Müller, L F Allsopp, G L Cooper, et al.
The British Journal of Dermatology|September 18, 2008
Novel and recurrent mutations in the 1B domain of keratin 1 in palmoplantar keratoderma with tonotubulesG Grimberg, I Hausser, F B Müller, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|June 1, 1986
Atrial antipressor natriuretic peptide: release mechanisms and vascular action in manF B Müller, P Erne, A E Raine, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Schweizerische Medizinische Wochenschrift|November 15, 1986
[Secretion of atrial natriuretic peptide: relation to atrial pressure and systemic blood pressure]F B Müller, P Erne, A E Raine, et al.
Hypertension (Dallas, Tex. : 1979)|January 1, 1986
Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamilR J Cody, S H Kubo, A B Covit, et al.
Journal of Cardiovascular Pharmacology|January 1, 1985
Adrenoceptors, calcium, and vasoconstriction in normal and hypertensive humansF R Bühler, P Bolli, P Erne, et al.
The American Journal of Cardiology|December 6, 1985
Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonistsW Kiowski, F R Bühler, M O Fadayomi, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1987
Greater vasodilator responsiveness to atrial natriuretic peptide in low-renin essential hypertensivesP Bolli, F B Müller, L Linder, et al.
Pharmacological Research Communications|September 1, 1988
Pathophysiological role of atrial natriuretic peptide in manF R Bühler, F B Müller, A E Raine, et al.
Journal of Cardiovascular Pharmacology|January 1, 1989
The vasodilating effect of atrial natriuretic peptide in normotensive and hypertensive humansP Bolli, F B Müller, L Linder, et al.
British Journal of Clinical Pharmacology|January 1, 1985
Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once dailyF B Müller, L F Allsopp, G L Cooper, et al.
The British Journal of Dermatology|September 18, 2008
Novel and recurrent mutations in the 1B domain of keratin 1 in palmoplantar keratoderma with tonotubulesG Grimberg, I Hausser, F B Müller, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|June 1, 1986
Atrial antipressor natriuretic peptide: release mechanisms and vascular action in manF B Müller, P Erne, A E Raine, et al.
Pageof 6